The Drug Discovery Services Companies Quadrant provides an in-depth analysis of the drug discovery services market, highlighting key players, technological advancements, and trends. Conducted by ...

Beam Therapeutics' said the Food and Drug Administration granted generative medicine advanced therapy designation to its sickle cell disease treatment BEAM-101.

Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene ...

T O APPRECIATE the dilemmas the Food and Drug Administration (FDA) faces when it reviews new drugs targeting rare diseases, ...

Kedrion is proud to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to ...

In August 2025, Dren Bio announced a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics ...

Kedrion Biopharma receives US FDA orphan drug designation for plasma-derived treatment for congenital aceruloplasminemia: Forte Lee, New Jersey Saturday, August 9, 2025, 17:00 Hrs ...

Hatteras was founded in 2000 with the closing of Hatteras Venture Partners I, a seed-stage venture fund with $2.93 million in capital. Today, the firm is focused on seed- and early stage companies in ...

More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for ...

Key highlights Lundbeck's total revenue grew by +14% CER[1] (+14% DKK) to DKK 12,258 million in the first six months of 2025. Growth in the U.S. and Europe was the driver of this strong performance. U ...

DYNE-251 received FDA breakthrough therapy designation, showcasing its potential for patients with Duchenne muscular ...

Key Points EPS (GAAP) matched estimates at $(0.26), reflecting cost controls but ongoing net losses and no revenue. Positive clinical milestones achieved for BX211 (diabetic foot osteomyelitis) and ...